OCALA, Fla. — AIM ImmunoTech Inc. today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer. “Approval from the governing ethics board...
Latest News
OCALA, Fla. — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center (“UPMC”) Phase 2 clinical trial – in which AIM and Merck Sharp & Dohme (“Merck”) are collaborators –...
OCALA, Fla. — AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX...
Rockville, MD – AIM-HI Accelerator Fund is proud to celebrate a significant milestone in the journey of one of its esteemed portfolio companies, Yiviva. A clinical-stage platform biotechnology company, Yiviva has entered into a Memorandum of Understanding (MOU) with AstraZeneca China, a multinational biopharmaceutical leader. AIM-HI was established with a...
LONDON — Privately owned UK biotech company Daval International Limited (http://www.davalinternational.com) has been informed by Australia’s Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND),...
CAMBRIDGE, Mass. — AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced the first patient has been dosed in the global Phase 1 clinical trial of AIR-001, AIRNA’s potential best-in-class RNA-editing candidate for the treatment of alpha-1 antitrypsin deficiency...
MARIETTA, Ga. — Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for its investigational biologic, zelpultide alfa, in its initial indication for the prevention...
NEW YORK & CAMBRIDGE, Mass. — Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1...
NEW YORK, NY and CAMBRIDGE, Mass. — Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095 for the treatment of myelofibrosis, a debilitating blood cancer that...
KIGALI, Rwanda — Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid-nanoparticle therapeutics and vaccines for infectious diseases that disproportionately affect the majority world, together with the TASK Clinical Research Center in South Africa, today announced positive results from the single-ascending-dose (SAD) portion of the first-in-human Phase 1 study of AKG-100,...